Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery

Van Bergen, Tine; Zahn, Grit; Caldirola, Patrizia; Fsadni, Mario; Caram-Lelham, Ninus; Vandewalle, Evelien; Moons, Lieve; Stalmans, Ingeborg

doi:10.1167/iovs.16-19751

Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery

Author:

Van Bergen, Tine

Zahn, Grit ; Caldirola, Patrizia ; Fsadni, Mario ; Caram-Lelham, Ninus ; Vandewalle, Evelien ; Moons, Lieve ; Stalmans, Ingeborg

Keywords:

Science & Technology, Life Sciences & Biomedicine, Ophthalmology, glaucoma surgery, wound healing, integrin, MITOMYCIN-C, PRECLINICAL EVALUATION, FIBRONECTIN RECEPTOR, EXTRACELLULAR-MATRIX, ADHESION RECEPTORS, CELL-ADHESION, EXPRESSION, GROWTH, BEVACIZUMAB, ALPHA(5)BETA(1), Aminoquinolines, Animals, Conjunctiva, Disease Models, Animal, Filtering Surgery, Follow-Up Studies, Glaucoma, Immunohistochemistry, Injections, Integrin alpha5beta1, Mice, Mice, Inbred C57BL, Ophthalmic Solutions, Postoperative Period, Wound Healing, 06 Biological Sciences, 11 Medical and Health Sciences, Ophthalmology & Optometry, 3212 Ophthalmology and optometry

Abstract:

To evaluate the therapeutic potential of the small molecule integrin α5β1 inhibitor, CLT-28643, to improve the filtering surgery outcome in a mouse model. Different dose regimens and administration routes of the inhibitor were compared with mitomycin C (MMC), the gold standard in clin ical practice.